Xenon Pharmaceuticals (XENE) Expected to Announce Earnings on Monday

Key Points

• Xenon Pharmaceuticals is expected to announce its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($1.03) per share.
• In its last earnings report, the company beat estimates with a loss of ($0.83) per share and reported revenue of $7.50 million, significantly higher than the forecast of $1.64 million.
• Xenon Pharmaceuticals currently has a market cap of $2.68 billion and an average analyst rating of "Moderate Buy" with a consensus price target of $54.82.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Monday, August 11th. Analysts expect Xenon Pharmaceuticals to post earnings of ($1.03) per share for the quarter.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating analysts' consensus estimates of ($0.90) by $0.07. The firm had revenue of $7.50 million during the quarter, compared to analyst estimates of $1.64 million. During the same quarter in the previous year, the business posted ($0.62) earnings per share. On average, analysts expect Xenon Pharmaceuticals to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Xenon Pharmaceuticals Price Performance

Shares of XENE traded up $1.81 during midday trading on Tuesday, reaching $34.97. The stock had a trading volume of 1,701,888 shares, compared to its average volume of 885,656. Xenon Pharmaceuticals has a 1-year low of $26.74 and a 1-year high of $46.00. The company's fifty day simple moving average is $31.58 and its two-hundred day simple moving average is $34.24. The company has a market cap of $2.68 billion, a price-to-earnings ratio of -10.83 and a beta of 1.16.

Wall Street Analysts Forecast Growth

XENE has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, May 13th. Royal Bank Of Canada reduced their target price on shares of Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Wall Street Zen cut shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. The Goldman Sachs Group reduced their price objective on shares of Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Finally, Evercore ISI assumed coverage on shares of Xenon Pharmaceuticals in a research report on Wednesday, May 14th. They set an "outperform" rating and a $55.00 target price for the company. One analyst has rated the stock with a sell rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $54.82.

Institutional Trading of Xenon Pharmaceuticals

A hedge fund recently raised its stake in Xenon Pharmaceuticals stock. Goldman Sachs Group Inc. lifted its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 7.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 442,732 shares of the biopharmaceutical company's stock after acquiring an additional 32,486 shares during the period. Goldman Sachs Group Inc. owned 0.58% of Xenon Pharmaceuticals worth $14,854,000 as of its most recent filing with the SEC. Institutional investors own 95.45% of the company's stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.